Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 8 -0.25 (-3.03%)
As of 04:14 AM Eastern
Compare

CRTX vs. BZT, CTL, GSP, KDNC, and KEN

Should you buy CRISM Therapeutics stock or one of its competitors? CRISM Therapeutics's main competitors and comparable companies include Bezant Resources (BZT), CleanTech Lithium (CTL), Gensource Potash (GSP), Cadence Minerals (KDNC), and Kendrick Resources (KEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "metals & mining" industry.

How does CRISM Therapeutics compare to Bezant Resources?

CRISM Therapeutics (LON:CRTX) and Bezant Resources (LON:BZT) are both small-cap materials companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Bezant Resources has lower revenue, but higher earnings than CRISM Therapeutics. Bezant Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K18.10-£792.20K-£4.90N/A
Bezant ResourcesN/AN/A-£8.40K-£0.00N/A

Bezant Resources' return on equity of -47.20% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
Bezant Resources N/A -47.20%-41.17%

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.5% of Bezant Resources shares are held by institutional investors. 50.2% of CRISM Therapeutics shares are held by company insiders. Comparatively, 7.1% of Bezant Resources shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CRISM Therapeutics has a beta of 0.592, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Bezant Resources has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Bezant Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Bezant Resources Neutral

Summary

Bezant Resources beats CRISM Therapeutics on 5 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to CleanTech Lithium?

CRISM Therapeutics (LON:CRTX) and CleanTech Lithium (LON:CTL) are both small-cap materials companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

CleanTech Lithium's return on equity of -22.32% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
CleanTech Lithium N/A -22.32%-13.50%

CleanTech Lithium has a consensus price target of GBX 17, indicating a potential upside of 136.44%. Given CleanTech Lithium's stronger consensus rating and higher possible upside, analysts plainly believe CleanTech Lithium is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CleanTech Lithium
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

CRISM Therapeutics has higher revenue and earnings than CleanTech Lithium. CleanTech Lithium is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K18.10-£792.20K-£4.90N/A
CleanTech LithiumN/AN/A-£2.19M-£1.60N/A

CRISM Therapeutics has a beta of 0.592, suggesting that its share price is 41% less volatile than the broader market. Comparatively, CleanTech Lithium has a beta of -0.79, suggesting that its share price is 179% less volatile than the broader market.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled CleanTech Lithium'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
CleanTech Lithium Neutral

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 0.5% of CleanTech Lithium shares are held by institutional investors. 50.2% of CRISM Therapeutics shares are held by insiders. Comparatively, 3.6% of CleanTech Lithium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CleanTech Lithium beats CRISM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CRISM Therapeutics compare to Gensource Potash?

CRISM Therapeutics (LON:CRTX) and Gensource Potash (LON:GSP) are both small-cap materials companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Gensource Potash'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Gensource Potash Neutral

CRISM Therapeutics has a beta of 0.592, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Gensource Potash has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

CRISM Therapeutics has higher revenue and earnings than Gensource Potash. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Gensource Potash, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K18.10-£792.20K-£4.90N/A
Gensource PotashN/AN/A-£6.58M-£0.01N/A

Gensource Potash's return on equity of -45.96% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
Gensource Potash N/A -45.96%-10.31%

0.3% of CRISM Therapeutics shares are held by institutional investors. 50.2% of CRISM Therapeutics shares are held by company insiders. Comparatively, 6.2% of Gensource Potash shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CRISM Therapeutics beats Gensource Potash on 5 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to Cadence Minerals?

Cadence Minerals (LON:KDNC) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

0.0% of Cadence Minerals shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 6.5% of Cadence Minerals shares are held by company insiders. Comparatively, 50.2% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cadence Minerals has a net margin of 875.38% compared to CRISM Therapeutics' net margin of 0.00%. Cadence Minerals' return on equity of -12.58% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadence Minerals875.38% -12.58% -3.99%
CRISM Therapeutics N/A -119.45%-26.77%

Cadence Minerals has a beta of 1.795, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.592, suggesting that its stock price is 41% less volatile than the broader market.

CRISM Therapeutics has higher revenue and earnings than Cadence Minerals. Cadence Minerals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadence MineralsN/AN/A-£5.72M-£0.59N/A
CRISM Therapeutics£352K18.10-£792.20K-£4.90N/A

In the previous week, Cadence Minerals' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Cadence Minerals Neutral
CRISM Therapeutics Neutral

Summary

Cadence Minerals and CRISM Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Kendrick Resources?

Kendrick Resources (LON:KEN) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

0.0% of Kendrick Resources shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 19.1% of Kendrick Resources shares are owned by company insiders. Comparatively, 50.2% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kendrick Resources has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.592, suggesting that its share price is 41% less volatile than the broader market.

CRISM Therapeutics has a net margin of 0.00% compared to Kendrick Resources' net margin of -227,572.12%. Kendrick Resources' return on equity of 3,889.95% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kendrick Resources-227,572.12% 3,889.95% -12.85%
CRISM Therapeutics N/A -119.45%-26.77%

In the previous week, Kendrick Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Kendrick Resources and 0 mentions for CRISM Therapeutics. Kendrick Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Kendrick Resources Neutral
CRISM Therapeutics Neutral

CRISM Therapeutics has higher revenue and earnings than Kendrick Resources. Kendrick Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kendrick ResourcesN/AN/A-£1.15M-£0.87N/A
CRISM Therapeutics£352K18.10-£792.20K-£4.90N/A

Summary

CRISM Therapeutics beats Kendrick Resources on 6 of the 11 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsMetals & Mining IndustryMaterials SectorLON Exchange
Market Cap£6.37M£3.62B£4.70B£2.84B
Dividend YieldN/A5.00%4.30%5.10%
P/E Ratio-1.6326.6426.7323.37
Price / Sales18.108.885.915.02
Price / CashN/A22.8820.8920.23
Price / Book0.194.464.112.51
Net Income-£792.20K£127.64M£159.56M£5.88B
7 Day Performance-5.88%-1.53%-1.12%0.73%
1 Month Performance-9.60%-7.96%-6.05%-1.90%
1 Year Performance-27.27%8.38%7.95%7.19%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 8
-3.0%		N/A-24.2%£6.37M£352KN/A4
BZT
Bezant Resources
N/AGBX 0.12
-3.3%		N/A+34.9%£27.52MN/AN/A5
CTL
CleanTech Lithium
N/AGBX 6.50
-3.8%		GBX 17
+161.5%		+18.8%£25.56MN/AN/A20
GSP
Gensource Potash
N/AN/AN/AN/A£23.61MN/AN/AN/A
KDNC
Cadence Minerals
N/AGBX 4.40
-3.2%		N/A+35.4%£21.08MN/AN/A6

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...
Behind the Markets | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel